Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dana Kappel
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0002-2476-6372
Observed ORCID:
0000-0002-2476-6372
OpenAlex ID:
A5016209357
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer
2025
·
Melanie Royce
, Mirat Shah
, et al.
·
Clinical Cancer Research
·
46
A Comparison of FDA and EMA Pregnancy and Lactation Labeling
2023
·
Dana Kappel
, Leyla Sahin
, et al.
·
Clinical Pharmacology & Therapeutics
·
32
PDF
FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma
2026
·
William F. Maguire
, Elaine Chang
, et al.
·
Clinical Cancer Research
·
1
PDF
Supplementary Table S1 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
2026
·
William F. Maguire
, Elaine Chang
, et al.
Supplementary Figure S2 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
2026
·
William F. Maguire
, Elaine Chang
, et al.
Data from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
2026
·
William F. Maguire
, Elaine Chang
, et al.
Supplementary Table S2 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
2026
·
William F. Maguire
, Elaine Chang
, et al.
Supplementary Figure S1 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
2026
·
William F. Maguire
, Elaine Chang
, et al.
Supplementary Table S3 from FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
2026
·
William F. Maguire
, Elaine Chang
, et al.
Qualitative Analysis of Inquiries Received by FDA Regarding Conduct of Clinical Trials during the Covid-19 Public Health Emergency
2024
·
Marijo Kambere
, Hong Vu
, et al.
·
Therapeutic Innovation & Regulatory Science
Show more works
View as search
Works count:
10
Citation count:
79
H-index:
2
I10-index:
2
Year
Topic
Type